Clinical Advances in Viral-Vectored Influenza Vaccines
AbstractInfluenza-virus-mediated disease can be associated with high levels of morbidity and mortality, particularly in younger children and older adults. Vaccination is the primary intervention used to curb influenza virus infection, and the WHO recommends immunization for at-risk individuals to mitigate disease. Unfortunately, influenza vaccine composition needs to be updated annually due to antigenic shift and drift in the viral immunogen hemagglutinin (HA). There are a number of alternate vaccination strategies in current development which may circumvent the need for annual re-vaccination, including new platform technologies such as viral-vectored vaccines. We discuss the different vectored vaccines that have been or are currently in clinical trials, with a forward-looking focus on immunogens that may be protective against seasonal and pandemic influenza infection, in the context of viral-vectored vaccines. We also discuss future perspectives and limitations in the field that will need to be addressed before new vaccines can significantly impact disease levels. View Full-Text
Share & Cite This Article
Sebastian, S.; Lambe, T. Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines 2018, 6, 29.
Sebastian S, Lambe T. Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines. 2018; 6(2):29.Chicago/Turabian Style
Sebastian, Sarah; Lambe, Teresa. 2018. "Clinical Advances in Viral-Vectored Influenza Vaccines." Vaccines 6, no. 2: 29.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.